Wells Fargo lowered the firm’s price target on Cigna (CI) to $300 from $354 and keeps an Equal Weight rating on the shares. The firm’s 2026 / 2027 / 2028 EPS estimates also decrease 10% / 13% / 14% following PBM pressures in 2026. While Wells is sympathetic to arguments that PBM earnings may be overly discounted, low visibility and lack of catalysts keeps the firm on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target lowered to $333 from $387 at TD Cowen
- Cigna price target lowered to $330 from $370 at Goldman Sachs
- Cigna’s Strategic Transition and Growth Prospects Justify Buy Rating
- Cigna price target lowered to $350 from $385 at Raymond James
- Cigna price target lowered to $310 from $375 at Truist
